Pridopidine, an investigational sigma-1 receptor agonist, was one of multiple promising therapeutics studied as part of the Phase II HEALEY-ALS platform trial. Michael Hayden, MB, ChB, PhD, FRCP, FRSC, The University of British Columbia, Vancouver, Canada, talks on the findings of the pridopidine arm and the plans for a Phase III study. Pridopidine was well tolerated, but did not meet the primary endpoint of change from baseline to 24 weeks in ALSFRS-R total in the overall study population. However, when assessing only those with early ALS (symptom onset ≤18 months), significant benefits were seen on ALSFRS-R total, compared to placebo. Respiratory function, dyspnea, and speech were also improved in those receiving pridopidine, compared to placebo. Prof. Hayden outlines plans for a Phase III study later this year. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
